Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAZ-AVI vs meropenem for nosocomial pneumonia (including ventilator-associated pneumonia)
CTR20130655Phase 3Completed
- Sponsor
- GSK
- Start
- May 2014
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ceftazidime + avibactam in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), sponsored by GSK. Started May 2014; status: completed.
02
Drugs
ceftazidime + avibactam
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on CTR20130655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130655.